evipedia.ai
← Back

Progesterone for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Micronized Progesterone, Oral Micronized Progesterone, Bioidentical Progesterone, Natural Progesterone, P4, Prometrium, Utrogestan

Motivation

Progesterone is a hormone the ovaries release after each egg is released, with smaller amounts made by the adrenal glands and, in pregnancy, by the placenta. Its level rises and falls across the monthly cycle and drops to very low values once the ovaries stop releasing eggs. The material used in treatment is chemically identical to what the body makes, which sets it apart from the laboratory-altered stand-ins that filled hormone therapy for decades.

Its first settled medical use was protecting the lining of the uterus in women taking estrogen, because estrogen alone thickens that lining. Interest then widened. The hormone breaks down into substances that act on the brain’s main calming system, and people who take it at bedtime often describe deeper sleep. Debate continues over whether it is meaningfully safer than the altered stand-ins, how long it can be used, and whether creams applied topically deliver anything useful at all.

This review examines what the evidence shows about progesterone for people focused on long-term health: which effects human trials actually support, which rest on weaker ground, what the risks are, how it is dosed, sourced and monitored, and where the picture is still unsettled.

Benefits - Risks - Protocol - Conclusion

High-level overviews of progesterone and of the hormone therapy it forms part of, drawn from expert platforms rather than the primary trial literature.

No item from Rhonda Patrick’s foundmyfitness.com is listed: the web and on-site searches returned tag and topic index pages that catalogue progesterone mentions, which this section excludes, alongside short research-summary story items on progesterone in traumatic brain injury and in animal tumour work — none of them an article or episode discussing progesterone in depth.

Grokipedia

  • Progesterone

    Reference article covering progesterone’s biosynthesis, receptor biology, chemistry and medical uses, useful as an orientation to the molecule before the trial evidence assessed in the sections below.

Examine

  • Progesterone

    Examine covers progesterone as a measured outcome rather than a supplement, grading which compounds shift progesterone levels; it does not review prescription progesterone as a therapy.

ConsumerLab

No dedicated ConsumerLab article on progesterone exists. Progesterone in the form covered by this review is a prescription medication, and ConsumerLab does not test prescription medications; its only progesterone content sits inside a member-gated menopause supplements report that tests over-the-counter progesterone creams alongside herbal products.

Systematic Reviews

Systematic reviews and meta-analyses covering progesterone’s claimed benefits and its principal safety questions.

Three of these five reviews come from a single Bern-led expert panel publishing in Climacteric, the journal of the International Menopause Society — a professional body whose members are clinicians who prescribe hormone therapy and whose meetings and research receive support from hormone manufacturers, including the maker of the branded oral progesterone capsule. Their conclusions are favourable to the intervention their membership prescribes, which is a structural conflict of interest to weigh when reading them, and the same caution applies symmetrically to the trial groups whose funding depends on demonstrating progesterone’s distinctiveness.

Mechanism of Action

Progesterone works through two routes. Genomically, it binds nuclear progesterone receptors PR-A and PR-B (two forms of the same receptor protein) and switches on genes that halt estrogen-driven division of the uterine lining, partly by reducing estrogen receptor numbers and by inducing 17β-hydroxysteroid dehydrogenase type 2, an enzyme converting potent estradiol into weaker estrone. Non-genomically, it is reduced by 5α-reductase and 3α-hydroxysteroid dehydrogenase into allopregnanolone, a brain-active steroid that amplifies signalling at the GABA-A receptor (gamma-aminobutyric acid type A receptor, the brain’s principal calming switch). It also blocks the mineralocorticoid receptor, the salt-retaining receptor aldosterone acts on, giving a mild fluid-shedding effect that progestins (laboratory-modified stand-ins for progesterone) lack.

Pharmacologically it is highly fat-soluble, distributing widely into fat, brain and breast tissue. A 200 mg oral micronized capsule peaks near 17 ng/mL at about 2.8 hours and returns to baseline by 24 hours, so its working half-life is only a few hours (Maxson & Hargrove, 1985). First-pass liver metabolism runs through 5α- and 5β-reduction and CYP3A4-mediated 6β-hydroxylation, CYP3A4 being the main drug-clearing liver enzyme (Niwa et al., 2020). It is not receptor-selective, weakly engaging androgen and glucocorticoid receptors.

Two accounts compete. One attributes the sleep and calming effects to allopregnanolone rather than progesterone; the other to direct receptor action in brain and vascular tissue. Likewise, progesterone’s apparent breast safety is read either as a genuine consequence of its receptor profile or as residual confounding in the observational cohorts that produced it.

Historical Context & Evolution

Progesterone was isolated in 1934 by four laboratories working in parallel and named the following year for sustaining gestation. Its original uses were obstetric. Supply limited it until Russell Marker showed in the 1940s that diosgenin from Mexican yams could be degraded to progesterone, collapsing its cost.

Two problems pushed clinicians away from the molecule: orally administered progesterone was poorly absorbed, and oil-based injections were painful. Chemists built orally active analogues, norethindrone in 1951 and medroxyprogesterone acetate soon after, and these progestins filled contraception and hormone therapy for four decades.

Katharina Dalton reported from the 1950s onward that progesterone suppositories relieved premenstrual syndrome, and treated many women on that basis. Her reports were uncontrolled case series. A later systematic review of controlled trials found the effect small and not clearly separable from placebo (Wyatt et al., 2001). Those trials pooled varied doses and criteria, so the biology is not closed; what controlled data do not support is the size of benefit she described.

Micronization, grinding the crystals fine enough to absorb, solved the delivery problem in the 1980s; oral capsules were licensed in France in 1980 and the United States in 1998. When a large trial reported a breast cancer signal in 2002 for a regimen containing medroxyprogesterone acetate (Rossouw et al., 2002), attention swung back to whether progesterone behaves the same way. That question remains open: European cohorts favour progesterone, no randomized trial has tested that endpoint, and readings of the 2002 result shift as subgroups are reanalysed.

Expected Benefits

High 🟩 🟩 🟩

Protection of the Uterine Lining During Estrogen Therapy

Estrogen taken alone drives continuous proliferation of the endometrium (the lining of the uterus), which progresses to hyperplasia (overgrowth) and raises endometrial cancer risk. Progesterone opposes this by switching the lining from a growth to a secretory state. A three-year randomized controlled trial found cyclic progesterone matched placebo for hyperplasia rates, and a systematic review established the effective regimen — 200 mg orally for 12–14 days per month for up to five years — while finding transdermal progesterone ineffective for this purpose (PEPI Trial, 1996; Stute et al., 2016).

Magnitude: Over three years, simple hyperplasia occurred in 27.7% of women on unopposed estrogen and atypical hyperplasia in 11.8%, against 0.8% and 0% on placebo; adding 200 mg cyclic progesterone returned rates to placebo level (p = 0.16, a p-value this high meaning the remaining difference from placebo could readily be chance).

Improved Sleep Onset and Deeper Sleep

Progesterone’s metabolite allopregnanolone amplifies the brain’s principal calming signal, which plausibly explains its sleep effects. A meta-analysis of nine randomized controlled trials in 388 participants, mostly postmenopausal women, found faster sleep onset on progesterone though not consistently longer total sleep or better sleep efficiency. A separate physiology study using overnight brain-wave recording found progesterone did not alter already-normal sleep but restored it when sleep was disrupted, behaving as a regulator rather than a sedative (Nolan et al., 2021; Caufriez et al., 2011).

Magnitude: Pooled across four trials, sleep onset latency improved with an effect size of 7.10 (95% confidence interval — the range the true effect most plausibly falls in — 1.30 to 12.91); in the physiology study, wakefulness after sleep onset was 53% lower and deep-sleep duration roughly 50% higher than on placebo.

Medium 🟩 🟩

Reduction of Hot Flushes and Night Sweats ⚠️ Conflicted

Progesterone at 300 mg nightly reduced hot flushes and night sweats in healthy postmenopausal women in a single 12-week randomized controlled trial, which a systematic review identified as the largest positive oral result. A later four-month trial in perimenopausal women, whose symptoms fluctuate with residual ovarian activity, missed significance, though it was underpowered and could not exclude a worthwhile effect (Hitchcock & Prior, 2012; Prior et al., 2023; Dolitsky et al., 2020). Net: real after the final period, unproven during the transition.

Magnitude: In postmenopausal women the daily symptom score fell 4.3 points more than on placebo (95% confidence interval 1.9 to 6.6), a 58.9% improvement against 23.5% on placebo; in perimenopausal women the placebo-adjusted reduction was 1.51 points with a confidence interval spanning no effect (−0.95 to 3.97).

Preserved Rise in High-Density Lipoprotein Cholesterol Compared With Synthetic Progestins

Synthetic progestins blunt the increase in HDL cholesterol (high-density lipoprotein, the fraction associated with lower cardiovascular risk) that estrogen produces alone. In a three-year randomized controlled trial with HDL cholesterol as a pre-specified primary endpoint, the regimen using cyclic progesterone kept almost the whole estrogen-driven gain, separating statistically from both medroxyprogesterone regimens. The endpoint is a validated surrogate rather than a cardiovascular event, and this remains a single trial (PEPI Trial, 1995).

Magnitude: HDL cholesterol rose 0.11 mmol/L (4.1 mg/dL) on estrogen plus cyclic progesterone, against 0.03–0.04 mmol/L (1.2–1.6 mg/dL) on the medroxyprogesterone regimens and a fall of 0.03 mmol/L (1.2 mg/dL) on placebo.

Neutral Clot and Stroke Risk Compared With Synthetic Progestins

Oral estrogen raises the risk of venous thromboembolism (blood clots forming in veins and travelling to the lungs). A French case-control study of 271 first clot events found that the progestin paired with estrogen matters: micronized progesterone carried no detectable excess, while norpregnane progestins (a synthetic subclass including nomegestrol acetate) roughly quadrupled risk. A systematic review of twelve studies reached the same conclusion for clots and ischaemic stroke, while noting that no study used heart attack as a primary endpoint (Canonico et al., 2007; Kaemmle et al., 2022).

Magnitude: Odds ratio (a measure of how much more likely an outcome is) for a first clot was 0.7 (95% confidence interval 0.3 to 1.9) with micronized progesterone and 3.9 (1.5 to 10.0) with norpregnane progestins, against 4.2 (1.5 to 11.6) for oral estrogen itself.

Neutral Effect on Body Weight and Glucose Handling

Weight gain is a common reason women decline or stop hormone therapy. A systematic review of trials pairing estrogen with micronized progesterone found body weight either unchanged or reduced in normal-weight women, body mass index unchanged, and fasting glucose, fasting insulin and glycated haemoglobin (a three-month average of blood sugar) unchanged or improved in both diabetic and non-diabetic women. The reviewers attribute most of the metabolic movement to the estrogen component rather than to progesterone (Coquoz et al., 2019).

Magnitude: Direction is consistently neutral-to-favourable across weight, body mass index, fasting glucose, fasting insulin and glycated haemoglobin in normal-weight, overweight, diabetic and non-diabetic postmenopausal women; the review reports these directions and states that the underlying trials give no pooled outcome figure.

Low 🟩

Support for Bone Formation ⚠️ Conflicted

Progesterone acts on bone-forming cells. A meta-analysis links disturbed ovulation to spinal bone loss and estimates added density alongside anti-resorptive therapy (drugs that slow bone breakdown), but a two-year randomized trial found 300 mg alone tracked placebo (Prior, 2018; Liu & Muse, 2005). Net: unproven as standalone bone therapy.

Magnitude: Progesterone added to anti-resorptive therapy was estimated to gain 0.68% spinal bone density per year; used alone for two years it produced no significant change at the spine or femoral neck.

Speculative 🟨

Broader Slowing of Aging Processes

Progesterone receptors appear in vascular, skeletal, immune and nervous tissue, and a review proposes hormone restoration as a healthspan strategy (Rabinovici et al., 2025). The basis is mechanistic reasoning and animal work, untested in humans.

Benefit-Modifying Factors

  • CYP3A4 and CYP3A5 activity: First-pass 6β-hydroxylation runs through these liver enzymes, which break down steroids and many drugs. Rapid metabolisers and anyone on an enzyme-inducing drug reach lower peak levels from the same oral dose, blunting both sleep and symptom effects.

  • 5α-reductase and 3α-hydroxysteroid dehydrogenase capacity: These enzymes convert progesterone into allopregnanolone, the calming metabolite. Individual variation in their activity plausibly explains why identical doses produce profound sleepiness in some women and nothing in others.

  • Baseline estradiol and endogenous progesterone: Women still producing ovulatory progesterone gain less from supplementation, while those with negligible output and high estrogen exposure gain the most endometrial protection. A progesterone level drawn a week before the expected period distinguishes them.

  • Sex: Effects are established almost entirely in women. In men and in transgender women, progesterone’s role is unsettled; benefit claims rest on small studies and cannot be transferred from the postmenopausal trial evidence.

  • Pre-existing sleep disturbance: The sleep benefit appears when sleep is already disrupted rather than when it is normal, so women with insomnia or night sweats see larger gains than good sleepers, in whom trials found no change.

  • Age and menopausal stage: Benefit is clearest after the final period. Perimenopausal women, in whom symptoms fluctuate with residual ovarian activity, showed smaller and non-significant symptom effects, and no trial has tested benefit beyond roughly age 70.

  • Pre-existing conditions: Obesity alters steroid distribution into fat and may reduce circulating levels from a fixed dose; untreated thyroid disease and depression confound the symptom endpoints progesterone is judged on.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Sedation and Next-Day Psychomotor Slowing

Oral progesterone’s conversion to allopregnanolone amplifies the brain’s calming signal, producing drowsiness, slowed eye movements and subjective sedation. A placebo-controlled study in 15 women showed a single 400 mg dose measurably slowed saccadic eye velocity — a standard laboratory index of central nervous system depression — and increased rated sedation, and the menopausal trials recorded dizziness among their frequent complaints (van Broekhoven et al., 2006; Hitchcock & Prior, 2012). Bedtime dosing converts most of this from a liability into the sleep benefit.

Magnitude: Prescribing information for the oral capsule records dizziness in 24% of women on 400 mg against 4% on placebo, and in 15% on the 200 mg cyclic regimen; the same label carries a standing caution that the capsule causes transient dizziness and drowsiness, and lists sedation among its post-marketing reports without attaching a frequency to it. Sedation and slowed eye movement appear within roughly two hours of an oral dose and scale with dose, being marked at 400 mg. No trial has measured next-morning driving performance.

Failure of Endometrial Protection with Transdermal or Under-Dosed Regimens

Progesterone protects the uterine lining only at adequate dose, route and duration. A systematic review found that transdermal progesterone — the form sold in compounded and over-the-counter creams — achieves blood levels far too low to oppose estrogen and provides no endometrial protection, while oral dosing below 200 mg for 12–14 days per month has not been shown adequate. Using such a product alongside estrogen leaves the lining effectively unopposed (Stute et al., 2016; PEPI Trial, 1996).

Magnitude: Unopposed estrogen produced simple hyperplasia in 27.7% and atypical hyperplasia in 11.8% of women over three years against 0.8% and 0% on placebo — the rate a woman relying on transdermal progesterone is exposed to.

Bleeding, Spotting and Headache Driving Discontinuation

Cyclic progesterone produces a scheduled withdrawal bleed; continuous dosing produces irregular spotting that usually settles within six months but may not. Headache is the other frequent complaint. A systematic review of seven randomized controlled trials of progestin-only therapy found these side effects significant in five and severe enough to end treatment in a substantial minority (Dolitsky et al., 2020; Prior et al., 2023). Any bleeding that is new, heavy or persistent after twelve months requires imaging, because it is also the presenting sign of endometrial cancer.

Magnitude: Across the seven trials, 6% to 21% of participants discontinued because of bleeding or headache.

Bloating, Breast Tenderness and Fluid Shifts

Trials record bloating, breast tenderness, nausea and dizziness as common but rarely treatment-limiting. Progesterone’s block of the salt-retaining receptor argues against true fluid retention, so bloating is more likely gut-motility related; breast tenderness reflects progesterone receptor activity in breast tissue (Hitchcock & Prior, 2012).

Magnitude: In the three-year placebo-controlled trial behind the prescribing information (PEPI Trial, 1996), 200 mg cyclic progesterone produced breast tenderness in 27% of women against 6% on placebo, abdominal bloating in 12% against 5%, and abdominal pain in 10%; adverse events of any kind ended treatment in 9% of participants in the menopausal trials.

Medium 🟥 🟥

Negative Mood and Irritability in Susceptible Women ⚠️ Conflicted

Allopregnanolone’s effect on mood follows an inverted-U: very low and very high concentrations are calming, while intermediate ones, matching a normal cycle’s second half, provoke irritability and low mood in susceptible women. A randomized crossover study in 36 postmenopausal women found this pattern. Against it, a four-year randomized controlled trial using 200 mg cyclic progesterone found no adverse mood effect, and a perimenopausal trial found no rise in depression (Andréen et al., 2005; Gleason et al., 2015; Prior et al., 2023). Net: a minority effect, not a population one.

Magnitude: Negative mood rises only in women whose blood allopregnanolone lands in the intermediate range during treatment, not in those at low or high concentrations; the studies report symptom-scale differences over time without publishing a single effect-size figure.

Breast Cancer Risk Beyond Five Years of Use

Up to five years, progesterone does not appear to add breast cancer risk, and it compares favourably with synthetic progestins. Beyond five years the evidence thins and points the other way. An 80,377-woman prospective cohort found no excess with estrogen plus progesterone while estrogen with other progestins carried a clear excess, and the systematic review built on such data concluded that use beyond five years carries limited evidence of increased risk (Fournier et al., 2008; Stute et al., 2018). No randomized trial has run long enough to settle this.

Magnitude: Relative risk (how many times more likely an outcome is than in the comparison group) 1.00 (95% confidence interval 0.83 to 1.22) for estrogen plus progesterone versus never-use over a mean 8.1 postmenopausal years, against 1.69 (1.50 to 1.91) for estrogen with other progestins; beyond five years the direction turns upward on observational data only.

Low 🟥

Rise in Free Thyroxine

A post hoc analysis inside a 12-week randomized controlled trial found 300 mg nightly raised free thyroxine (the unbound, active thyroid hormone) relative to placebo. All 69 women had normal thyroid function throughout, so clinical meaning is undetermined; it matters mainly for anyone on thyroid replacement (Sathi et al., 2013).

Magnitude: Free thyroxine rose 2.5 pmol/L on progesterone against 1.7 pmol/L on placebo (difference 0.8 pmol/L, 95% confidence interval 0.0 to 1.6), with all values staying inside the reference range.

Speculative 🟨

Unknown Consequences of Long-Term Supraphysiologic Dosing

The 300 mg nightly regimen produces peaks above natural cycle levels, sustained for years but tested only for months. Concern rests on receptor biology in progesterone-responsive tissue and analogy with high-dose progestins, not human data.

Risk-Modifying Factors

  • CYP3A4-inducing and -inhibiting genotypes and drugs: Slow clearance raises peak levels and therefore sedation; rapid clearance undermines endometrial protection. This enzyme pathway is the single largest source of between-person variation in exposure.

  • Allopregnanolone sensitivity: Women with a history of premenstrual syndrome, premenstrual dysphoric disorder (its severe, disabling form) or postpartum depression appear disproportionately prone to progesterone-induced low mood, reflecting inherited differences in how the calming receptor responds.

  • Baseline liver function and albumin: Progesterone is cleared by the liver and largely protein-bound. Impaired liver function raises free hormone concentrations and prolongs sedation, which is why significant liver disease is a contraindication.

  • Sex: Safety data are almost entirely from women. In men, progesterone suppresses the pituitary hormones driving testosterone production, a risk that does not arise in the populations where it has been studied.

  • Pre-existing conditions: Active or past breast cancer, undiagnosed vaginal bleeding, current clotting disease and severe liver disease each convert a tolerable profile into an unacceptable one. Peanut allergy excludes the peanut-oil-based branded capsule specifically.

  • Age: Sedation, falls and next-morning drowsiness matter more with advancing age, and no safety data exist for initiation beyond roughly age 70 or for continuous use past ten years.

Key Interactions & Contraindications

  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St John’s wort): Caution. These accelerate progesterone breakdown and can drop levels below the threshold for endometrial protection. Mitigation: avoidance of the combination, or a levonorgestrel intrauterine device for endometrial protection.

  • CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): Monitor. Raised progesterone levels amplify sedation and dizziness. Mitigation: dose reduction, or earlier evening administration while the inhibitor is in use.

  • Benzodiazepines (lorazepam), “Z-drugs” (zolpidem), gabapentinoids (gabapentin, pregabalin, nerve-pain drugs that also sedate), opioids (oxycodone) and alcohol: Caution. Additive depression of the brain’s calming system risks excessive sedation, falls and impaired breathing during sleep. Mitigation: separation on different nights, or a reduced sedative dose.

  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine), the active ingredient in most night-time sleep aids and cold remedies: Caution. They add to progesterone’s sedation and next-morning drowsiness and carry their own fall risk in older women. Mitigation: a single bedtime sedating agent at a time.

  • Oral estrogen: Monitor. This is the intended pairing, but oral estrogen carries its own clot risk that progesterone does not offset. Mitigation: transdermal estradiol avoids the first-pass clotting effect while progesterone still protects the lining.

  • Thyroid hormone replacement (levothyroxine): Monitor. Progesterone raises free thyroxine slightly, so a stable dose may read differently on testing. Mitigation: a thyroid function recheck 8–12 weeks after starting.

  • Antihypertensives (lisinopril, amlodipine) and diuretics (spironolactone, hydrochlorothiazide): Monitor. Progesterone’s block of the salt-retaining receptor adds a mild sodium-losing effect. Mitigation: blood pressure and sodium checks after starting, where a spironolactone-type drug is already in use.

  • Sedating supplements (valerian, kava, high-dose melatonin, magnesium glycinate at large doses, cannabidiol): Caution. Additive next-morning drowsiness. Mitigation: introduction of one agent at a time rather than several stacked at bedtime.

  • Other interventions — cognitive behavioural therapy for insomnia: No pharmacological interaction; it is the main non-hormonal comparator for the sleep indication and can be run alongside without dose adjustment.

Populations who should avoid Progesterone:

  • Known, suspected or past breast cancer, and known progesterone-receptor-positive malignancy
  • Undiagnosed abnormal vaginal bleeding, until endometrial sampling or imaging has excluded malignancy
  • Active venous thromboembolism, active arterial thromboembolic disease, or stroke or myocardial infarction within the past 12 months
  • Severe liver impairment (Child-Pugh Class C, the most advanced grade of chronic liver failure) or active liver disease with liver enzymes above three times the upper limit of normal
  • Known allergy to peanuts, for the peanut-oil-based branded capsule specifically; an alternative formulation is required
  • Known or suspected pregnancy outside a supervised obstetric indication, and porphyria (a rare inherited disorder of pigment-precursor metabolism)

Risk Mitigation Strategies

  • Bedtime-only dosing: Converts sedation from an impairment risk into the sleep benefit, and keeps peak levels away from driving and work. Standard practice across every menopausal trial cited here.

  • Low starting dose with stepped titration from 100 mg to 200–300 mg: A two-week run-in at the lower dose identifies women prone to heavy next-morning drowsiness or low mood before committing to the full dose that drives symptom benefit.

  • Oral or vaginal route rather than transdermal cream for endometrial protection: Creams do not reach protective blood levels, leaving the uterine lining exposed to unopposed estrogen and its 27.7% three-year hyperplasia rate.

  • Minimum dose-days threshold of 200 mg for 12–14 days per month on cyclic regimens: Below this threshold, endometrial protection is unproven. Continuous 100 mg daily is the alternative validated regimen.

  • Investigation of any bleeding after twelve months of continuous use: Transvaginal ultrasound plus endometrial biopsy separates benign breakthrough spotting from hyperplasia or carcinoma, the outcome the therapy exists to prevent.

  • Continuation review at the five-year mark: Breast cancer evidence is reassuring to five years and thin beyond it, so five years is the point at which continuing becomes a decision rather than a default.

  • Separation from other bedtime sedatives: Combining progesterone with sleep medication, alcohol or sedating supplements risks falls and breathing suppression; single-agent introduction is what allows the effective component to be identified.

Therapeutic Protocol

  • Standard cyclic regimen: 200 mg orally at bedtime for 12–14 days each month alongside continuous estradiol. This is the dose-days combination validated for endometrial protection for up to five years; it produces a scheduled monthly bleed.

  • Standard continuous regimen: 100 mg orally at bedtime every day alongside estradiol. Avoids a scheduled bleed at the cost of irregular spotting in the first six months; favoured further from the final period.

  • Progesterone-alone regimen for symptoms: 300 mg at bedtime, used where estrogen is declined or contraindicated. This is the dose that produced the positive hot-flush result, and it is higher than the endometrial-protection dose.

  • Competing approach — the intrauterine device: A levonorgestrel intrauterine system provides endometrial protection with minimal systemic exposure. It forgoes progesterone’s sleep effect entirely, and neither approach is the default.

  • Competing approach — compounded creams and troches: Compounding pharmacies and the wider bioidentical movement popularised transdermal progesterone. Systematic review finds it does not protect the endometrium (Stute et al., 2016), a disagreement about evidence rather than preference.

  • Expert attribution: The 300 mg symptom protocol comes from Jerilynn Prior’s group at the Centre for Menstrual Cycle and Ovulation Research; the 200 mg for 12–14 days standard from the Bern-led expert panel, whose members earn from prescribing it.

  • Time of day: Bedtime only. Peak levels arrive near 2.8 hours after dosing, so evening administration aligns sedation with sleep and keeps morning concentrations low.

  • Half-life and dose splitting: Elevation persists at least six hours and clears by 24, so a single nightly dose is standard. Splitting doses reintroduces daytime sedation without improving endometrial protection.

  • Genetic considerations: CYP3A4 and CYP3A5 variants alter first-pass clearance, and 5α-reductase and 3α-hydroxysteroid dehydrogenase variation alters how much calming metabolite forms. No pharmacogenetic test currently guides dosing.

  • Sex-based differences: Dosing is derived entirely from female trials. Use in men and in transgender women is off-label at 100–200 mg, with efficacy still under randomized evaluation.

  • Age considerations: Older women tolerate 100 mg better than 300 mg because sedation and fall risk rise with age. No dosing data exist for initiation beyond roughly age 70.

  • Baseline biomarkers: A progesterone level drawn a week before the expected period identifies residual ovulation in perimenopause; estradiol establishes how much opposition the lining needs. Neither is titrated to a target on therapy.

  • Pre-existing conditions: Obesity, impaired liver function and untreated thyroid disease each change exposure or confound response. Significant hepatic impairment rules the oral route out rather than adjusting it.

Discontinuation & Cycling

  • Duration framing: Not lifelong by default. Progesterone is taken for as long as estrogen is taken, since its main job is protecting the lining; the five-year mark is where breast evidence thins and continuation becomes deliberate.

  • Stopping alongside estrogen: When estrogen stops, progesterone stops. Continuing progesterone alone serves no endometrial purpose, though some continue it for sleep, which is a separate decision with its own evidence.

  • Withdrawal effects: A withdrawal bleed follows cessation in women with an intact lining. Sleep quality and hot flushes typically revert toward baseline; one trial found no rebound worsening beyond baseline after stopping (Prior & Hitchcock, 2012).

  • Tapering: No taper is pharmacologically required, since the drug clears within 24 hours. Stepping 300 mg down to 100 mg over two to four weeks is used to soften the return of night sweats.

  • Cycling: Monthly cycling is a regimen choice for bleeding control and endometrial protection, not a strategy for maintaining efficacy. No tolerance to progesterone’s sleep or symptom effects has been demonstrated.

Sourcing and Quality

  • Prescription oral capsules: The validated form. Branded capsules (Prometrium, Utrogestan) and approved generics are made to pharmacopoeial standards with documented content and dissolution, which is what micronization-dependent absorption requires.

  • Peanut oil content: The branded United States capsule suspends progesterone in peanut oil. Sunflower-oil generics and European formulations exist; anyone with peanut allergy needs the specific excipient list, not just the drug name.

  • Compounded preparations: Compounding pharmacies supply creams, troches and non-standard capsule strengths. These are not subject to the same batch-testing requirements, and potency variation between batches has repeatedly been documented.

  • Over-the-counter progesterone creams: Sold as cosmetics or supplements. Independent testing has repeatedly found mislabelled or contaminated products, and regulators have acted against sellers making unsupported claims for them.

  • What to look for: An approved drug product with a national drug code or marketing authorisation number, stated micronized progesterone content in milligrams, a full excipient list, and a supplier that provides batch documentation on request.

  • Third-party testing: Relevant only to the over-the-counter cream market, where no approval process applies; for prescription capsules, regulatory approval already covers identity, potency and dissolution testing.

Practical Considerations

  • Time to effect: Sleep changes appear the first night. Hot-flush reduction builds over four to twelve weeks. Endometrial protection is immediate but only demonstrable by biopsy or imaging over months.

  • Pitfall — morning dosing: Taking progesterone in the morning produces daytime sedation and discards the sleep benefit. It is the single most common error and is fully avoidable.

  • Pitfall — relying on cream for protection: Using a transdermal cream while taking estrogen leaves the uterine lining unopposed. The cream may relieve symptoms subjectively while providing no protection at all.

  • Pitfall — confusing progesterone with progestins: Trial results for medroxyprogesterone acetate and norpregnane derivatives do not transfer to progesterone, and neither do progesterone’s reassuring clot and breast data transfer to them.

  • Regulatory status: A prescription medicine approved for endometrial protection and secondary amenorrhoea (periods that have stopped). Use for sleep, for hot flushes without estrogen, and in men or transgender women is off-label.

  • Cost and accessibility: Generic oral capsules are inexpensive and widely stocked, so cost is not a barrier. Compounded preparations cost substantially more and are typically not reimbursed.

  • Payer incentives: Oral progesterone and synthetic progestins are both cheap generics, so insurers and national systems have no systematic reason to favour one over the other; the reimbursement gap against cash-pay compounded products is the real structural asymmetry.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Conversion to allopregnanolone amplifies the brain’s calming signal, shortening sleep onset and deepening slow-wave sleep when sleep is already disturbed, with no effect on normal sleep. Bedtime administration is the standard timing, and next-morning drowsiness marks a dose set too high.

  • Nutrition: Indirect. Absorption of the micronized capsule improves with food, and a fat-containing evening meal raises bioavailability. Grapefruit juice inhibits the clearing enzyme and raises exposure. No nutrient depletion has been demonstrated, and body weight is unchanged on therapy.

  • Exercise: Largely none for training adaptation; no blunting of strength or hypertrophy gains has been shown. The practical interaction is indirect and favourable: better sleep supports recovery. Bedtime dosing means no timing conflict with training sessions at any hour.

  • Stress management: Potentiating in most women, paradoxical in a minority. Allopregnanolone dampens the stress axis, which underlies the calming effect; in women sensitive to mid-range concentrations it instead produces irritability. Stress-reduction practices and progesterone act on the same receptor pathway rather than competing.

Monitoring Protocol & Defining Success

Before starting, a baseline is established to confirm that progesterone is appropriate and to create the comparison points that later testing is read against. That baseline covers endometrial thickness by ultrasound in any woman with a uterus, a progesterone and an estradiol level to establish where ovarian output sits, liver enzymes, a lipid panel, fasting glucose and glycated haemoglobin, thyroid-stimulating hormone with free thyroxine, blood pressure, and breast imaging current to screening schedule. A two-week symptom and sleep diary completed before the first dose matters as much as the bloodwork, because the endpoints here are symptomatic.

Ongoing testing is light. Symptoms and sleep are reviewed at 4 weeks, thyroid function and liver enzymes at 8–12 weeks, and a full panel with blood pressure at 6 months and then every 6–12 months. Endometrial imaging is event-driven, triggered by new, heavy or persistent bleeding.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Endometrial thickness (transvaginal ultrasound) < 5 mm postmenopausal on therapy Direct read on whether the lining is protected The endpoint progesterone exists to control; repeated only when bleeding is new, heavy or persists past 12 months
Serum progesterone No established on-therapy target; track against the individual’s own pre-treatment value Confirms absorption, especially where response is absent Oral dosing gives erratic levels; drawn 2–4 hours post-dose where checked at all, and not a number the dose is titrated to
Estradiol 50–100 pg/mL on transdermal therapy Sets how much opposition the lining needs Drawn mid-patch or mid-gel-interval; read alongside endometrial thickness rather than alone
TSH and free T4 TSH 0.5–2.0 mIU/L; free T4 upper half of reference range Progesterone raises free thyroxine modestly TSH is thyroid-stimulating hormone; free T4 is free thyroxine, the active unbound thyroid hormone. Conventional TSH range extends to 4.0–4.5 mIU/L, wider than the functional target; rechecked 8–12 weeks after starting, and sooner where levothyroxine is in use
HDL-C and LDL-C HDL-C > 60 mg/dL; LDL-C < 100 mg/dL Progesterone preserves the estrogen-driven HDL gain that progestins blunt HDL-C is high-density lipoprotein cholesterol; LDL-C is low-density lipoprotein cholesterol. Conventional cut-offs are looser — HDL-C is flagged low only below 50 mg/dL in women and LDL-C only above 130 mg/dL. Fasting preferred for triglycerides; paired with apolipoprotein B where available
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c < 5.4% Confirms the expected metabolic neutrality holds individually HbA1c is glycated haemoglobin, a three-month average of blood sugar. Conventional thresholds are 100 mg/dL and 5.7%, looser than the functional targets; requires 8–12 hour fast
ALT and AST Both < 25 U/L Progesterone is cleared by the liver; impairment raises exposure and sedation ALT and AST are liver enzymes that rise when liver cells are stressed. Conventional upper limits near 40 U/L are considerably looser; checked at baseline and 8–12 weeks
Blood pressure < 120/80 mmHg Progesterone’s mild sodium-losing action can lower it further Measured seated after five minutes’ rest; relevant where antihypertensives are already in use

Qualitative markers carry as much weight as the panel here, since the benefits most people are seeking are experienced rather than measured.

  • Time to fall asleep and number of night awakenings, logged nightly
  • Frequency and intensity of hot flushes and night sweats, scored daily
  • Next-morning alertness, and whether drowsiness persists past the first hour awake
  • Mood stability and irritability, tracked specifically during the progesterone days of a cyclic regimen
  • Breast tenderness, bloating and any bleeding or spotting, with dates

Emerging Research

  • Progesterone against behavioural therapy for perimenopausal insomnia: NCT06497894, a Phase 4 randomized trial of 54 perimenopausal women, compares transdermal estradiol plus 200 mg oral micronized progesterone against cognitive behavioural therapy, with insomnia severity at week 10 as the primary endpoint.

  • Progesterone in gender-affirming hormone therapy: NCT06807580, a Phase 2 placebo-controlled trial of 40 transgender women taking 200 mg oral micronized progesterone, with psychological distress as its primary endpoint — a higher-dose, longer test of a widely used off-label practice that an earlier low-dose randomized trial left unresolved.

  • Joint pain at menopause: NCT06530459, a Phase 2/3 trial of 100 women, tests estradiol gel with 200 mg micronized progesterone for 12 days monthly, with and without strength training, against perceived joint pain — a symptom domain no existing trial has isolated.

  • Metabolic effects alongside weight-loss medication: NCT06715514, 96 postmenopausal women with type 2 diabetes receiving hormone therapy plus a glucagon-like peptide-1 agonist (a class of blood-sugar and appetite-regulating drugs), with change in glycated haemoglobin as the primary endpoint.

  • Evidence that could weaken the cognitive case: Gleason et al., 2024 re-examined 275 women roughly ten years after four years of hormone therapy with 200 mg cyclic progesterone and found no lasting cognitive benefit or harm, closing off a frequently claimed longevity rationale.

  • Evidence that could weaken the breast safety case: Stute et al., 2018 flagged limited evidence of increased breast cancer risk past five years. No randomized trial currently running is designed to resolve it, so the question will likely be settled by further cohort follow-up.

  • Open question — who responds: Whether variation in the enzymes converting progesterone to its calming metabolite predicts who gets the sleep benefit and who gets low mood is untested. A trial stratifying on that conversion would decide whether dosing can be personalised.

Conclusion

Progesterone is the body’s own hormone rather than a laboratory-modified stand-in, and that distinction carries real consequences. Its best-established use is protecting the lining of the uterus in women taking estrogen, where the dose, the timing and the route all have to be right — oral capsules work and topical creams do not, a point where a large part of the market and the evidence disagree. Taken at bedtime it shortens the time to fall asleep and deepens sleep in people whose sleep is already disturbed, and at higher doses it reduces hot flushes and night sweats after the final period, though the same effect did not hold up in the years leading into it.

Compared with the modified stand-ins it replaced, it looks better on blood-clot risk, on cholesterol and on breast cancer over the first five years. Past five years the evidence thins rather than turns, and no long trial has been run to close that gap. The common trade-offs are drowsiness, bleeding or spotting, and low mood in a minority who are sensitive to it.

Much of the favourable reading of the evidence comes from expert panels drawn from a professional body whose members prescribe this therapy and whose field receives manufacturer support, which is worth holding in mind, as is the fact that the reassuring long-term comparisons rest on observed populations rather than assigned ones.

Top - Benefits - Risks - Protocol